Found: 11
Select item for more details and to access through your institution.
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 6, p. 925, doi. 10.1177/13524585211047223
- By:
- Publication type:
- Article
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 13, p. 2052, doi. 10.1177/1352458521988926
- By:
- Publication type:
- Article
Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 8, p. 3803, doi. 10.1111/bcp.15332
- By:
- Publication type:
- Article
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
- Published in:
- Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1021-2
- By:
- Publication type:
- Article
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity.
- Published in:
- Annals of Clinical & Translational Neurology, 2024, v. 11, n. 10, p. 2792, doi. 10.1002/acn3.52171
- By:
- Publication type:
- Article
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
- Published in:
- Annals of Clinical & Translational Neurology, 2023, v. 10, n. 12, p. 2413, doi. 10.1002/acn3.51911
- By:
- Publication type:
- Article
(DXT15) Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the N-MOmentum Trial.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 21
- By:
- Publication type:
- Article
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 387, doi. 10.1007/s40262-021-01071-5
- By:
- Publication type:
- Article
B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2018, v. 11, p. 1, doi. 10.1177/1756286418761697
- By:
- Publication type:
- Article
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 6, p. 1795, doi. 10.1007/s40744-023-00593-7
- By:
- Publication type:
- Article
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 8, p. 945, doi. 10.1177/13524585231172145
- By:
- Publication type:
- Article